search
Back to results

PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya

Primary Purpose

HIV Antibody Positivity, PrEP Uptake

Status
Active
Phase
Not Applicable
Locations
Kenya
Study Type
Interventional
Intervention
Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Antibody Positivity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

The inclusion criteria for the study includes:

Being age 18 years and above.

Being HIV negative on a rapid HIV test conducted prior to interviews.

No pregnancy for females at the time of recruitment.

Active injection of illicit drugs in the six months preceding the study.

High multiple HIV risk and high HIV through sexual activities and sharing of injection equipment or syringes (the high multiple-risk group mixed unsafe drug use with unsafe sexual practices; the second group practiced high-risk sex with non-consistent condom combined with drug use; the moderate-risk group had limited unsafe sexual practices; and the "low-risk" group never had unprotected sex and never shared needles and other injection equipment).

Informed consent to participate inti the study.

The exclusion criteria includes:

Being a minor (below 18 years).

Those not actively injecting drugs.

Acute or chronic HIV infection

Those not consenting to participation into the study.

Pregnancy.

Sites / Locations

  • Pangani DIC, Ngara DIC, Githurai DIC, Kawangware DIC

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Intervention and control group

Control group

Arm Description

To establish the effect of navigation on PrEP uptake, adherence and retention among PWID.

To establish the effect of providing PrEP information through pamphlets on PrEP uptake, adherence and retention among PWID.

Outcomes

Primary Outcome Measures

PrEP uptake following either navigation or provision of pamphlets (Self-reported uptake reported through quantitative interviews)
Outcome 1: Uptake of PrEP following the study interventions (either navigation into PrEP or pamphlets) Outcome 2-Adherence to PrEP Outcome 3: Retention into PrEP following uptake
Retention into PrEP after uptake following either navigation or provision of pamphlets (Self-reported retention)
Retention into PrEP for 18 weeks (self-reported through interviews conducted by investigators))
Adherence to PrEP for 18 weeks (self reported through interviews conducted by investigators)
Adherence to PrEP after uptake following either navigation or provision of pamphlets (Self-reported adherence through interviews conducted by investigators)

Secondary Outcome Measures

HIV Status following Rapid HIV tests OraQuick rapid HIV 1 antibody tests
Seroconversion following PreP uptake or failure to take up PrEP in the 18 weeks of the RCT

Full Information

First Posted
July 6, 2022
Last Updated
July 19, 2022
Sponsor
University of Washington
Collaborators
Kenyatta National Hospital, Fogarty International Center of the National Institute of Health
search

1. Study Identification

Unique Protocol Identification Number
NCT05465265
Brief Title
PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya
Official Title
Pre-Exposure Prophylaxis for Prevention of Human Immunodeficiency Virus Transmission Among Sexual and Injecting Partners of People Who Inject Drugs in Nairobi, Kenya
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
July 30, 2022 (Anticipated)
Study Completion Date
July 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
Collaborators
Kenyatta National Hospital, Fogarty International Center of the National Institute of Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators broadly aim at determining barriers and facilitators to PrEP uptake and adherence and retention among the study participants. The investigators have the following specific objectives of determining: (1) the PrEP knowledge levels, attitudes, practices, and user experiences among injecting and sexual partners of PWID in Nairobi County (2) the socio-demographic, behavioural, and structural factors hindering the uptake of PrEP among PWID's sexual and injecting partners in Nairobi County; and (3) the effect of a theory-guided behavioural intervention (PrEP-UP) utilizing peer outreach and navigation on the uptake of PrEP by the study participants. The investigators hypothesize that: PWID's injecting and sexual partners in Nairobi City lack PrEP knowledge, and have poor attitudes practices, and user experiences about PrEP; less than 50.0% of the PWID's sexual and injecting partners in Nairobi County have socio-demographic, behavioural and structural factors hindering their uptake of PrEP; and a theory-guided behavioural intervention (PrEP-UP) utilizing peer outreach and navigation has no effect on the uptake of PrEP by the study participants.
Detailed Description
Background: The annual global number of new HIV infections among adults has remained unchanged over the last decade and it is largely fuelled by key populations among them people who inject drugs (PWID). Key populations in Kenya account for one-third of all new HIV infections and 18.3% of PWID in the country are living with HIV. Drug and substance use is on the increase in the country, with close to 4 out of 10 Kenyans reporting to have used a substance in their lifetime including injectable drugs thus fueling the spread of HIV. Pre-Exposure Prophylaxis (PrEP) is effective in the prevention of HIV transmission among PWID by over 70.0% if and when used correctly. However, uptake, adherence, scale-up of use, coverage and retention currently remain limited. Thus, effective interventions are needed to enhance the uptake of PrEP among PWID and their sexual and injecting partners in order to prevent HIV transmission. Objectives of the Study: Broadly, the investigators aim at determining PrEP uptake barriers and facilitators and adherence among the study participants and the sequel of a theory-guided behavioral intervention model (PrEP-UP) on the uptake of PrEP by the study participants. Specifically, the investigators aim at determining: (1) the PrEP knowledge levels, attitudes, practices and user experiences among the study participants(2) the socio-demographic, behavioural and structural factors hindering the uptake of PrEP among the study participants; and (3) the effect of a theory-guided behavioural intervention (PrEP-UP) utilizing peer outreach and navigation on the uptake of PrEP by the study participants. Methods: The investigators will conduct the study for twelve months (1st July 2021 to 30th June 2022) and they will use an implementation study through a pre-post design to assess 256 participants' self-reported PrEP uptake and retention before and after exposure to a theory-guided behavioural intervention (PrEP-UP) utilizing navigators and peer outreach for the 128 'cases' and PrEP information Pamphlet and list of health facilities offering PrEP for free in Nairobi County for the 128 'control' group members. The investigators will use four study sites namely Githurai, Kawangware, Ngara and Pangani PWID's hotspots within Nairobi City. The targeted study participants are PWID's sexual and injecting partners of ages 18 years and above. The investigators will recruit 256 study participants into the study by use of peers and social workers in the University of Washington's Needle and Syringe Program (NSP) sites in Githurai, Kawangware, Ngara and Pangani. The investigators will collect baseline data after recruitment while the interventions for both groups will be offered in a maximum 5 contact sessions with investigators and a follow-up of the participants will be done by the investigators at weeks 4, 8 and 12 to establish whether study participants have taken up PrEP by week 12 during which post-intervention data will be collected. Lastly, participants' self-reported PrEP retention will be documented by investigators at 18 weeks and HIV tests will be conducted on the participants by the investigators (optional) through OraQuick antibody HIV tests. The investigators will analyze: quantitative data through the Statistical Package for Social Sciences (SPSS) version 24 and: qualitative data through flow chart matrices to establish divergence and convergence of themes. Significance of the Study: Through the study, the investigators will contribute to the global call for the reduction in new HIV infections among PWIDs and their sexual and injecting partners. The study will further inform the investigators on the effectiveness-implementation science interventions and recommend the best PrEP scale-up approaches in addition to contributing to the global scientific knowledge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Antibody Positivity, PrEP Uptake

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study may have two arms: "Cases will be navigated into PrEP services" and the "Control group will just be given PrEP information pamphlets"
Masking
Care Provider
Masking Description
Cases : Navigation into PrEP Control group: Provision of pamphlets with information on PrEP.
Allocation
Randomized
Enrollment
256 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention and control group
Arm Type
Active Comparator
Arm Description
To establish the effect of navigation on PrEP uptake, adherence and retention among PWID.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
To establish the effect of providing PrEP information through pamphlets on PrEP uptake, adherence and retention among PWID.
Intervention Type
Behavioral
Intervention Name(s)
Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)
Other Intervention Name(s)
Control Group: Provision of PrEP pamphlets has is expected to have no effect on uptake of PrEP, adherence to PrEP and retention into PrEP
Intervention Description
Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
Primary Outcome Measure Information:
Title
PrEP uptake following either navigation or provision of pamphlets (Self-reported uptake reported through quantitative interviews)
Description
Outcome 1: Uptake of PrEP following the study interventions (either navigation into PrEP or pamphlets) Outcome 2-Adherence to PrEP Outcome 3: Retention into PrEP following uptake
Time Frame
12 weeks
Title
Retention into PrEP after uptake following either navigation or provision of pamphlets (Self-reported retention)
Description
Retention into PrEP for 18 weeks (self-reported through interviews conducted by investigators))
Time Frame
18 weeks
Title
Adherence to PrEP for 18 weeks (self reported through interviews conducted by investigators)
Description
Adherence to PrEP after uptake following either navigation or provision of pamphlets (Self-reported adherence through interviews conducted by investigators)
Time Frame
18 weeks
Secondary Outcome Measure Information:
Title
HIV Status following Rapid HIV tests OraQuick rapid HIV 1 antibody tests
Description
Seroconversion following PreP uptake or failure to take up PrEP in the 18 weeks of the RCT
Time Frame
18 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
The inclusion criteria for the study includes: Being age 18 years and above. Being HIV negative on a rapid HIV test conducted prior to interviews. No pregnancy for females at the time of recruitment. Active injection of illicit drugs in the six months preceding the study. High multiple HIV risk and high HIV through sexual activities and sharing of injection equipment or syringes (the high multiple-risk group mixed unsafe drug use with unsafe sexual practices; the second group practiced high-risk sex with non-consistent condom combined with drug use; the moderate-risk group had limited unsafe sexual practices; and the "low-risk" group never had unprotected sex and never shared needles and other injection equipment). Informed consent to participate inti the study. The exclusion criteria includes: Being a minor (below 18 years). Those not actively injecting drugs. Acute or chronic HIV infection Those not consenting to participation into the study. Pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cosmas Gitobu
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pangani DIC, Ngara DIC, Githurai DIC, Kawangware DIC
City
Nairobi
ZIP/Postal Code
254
Country
Kenya

12. IPD Sharing Statement

Learn more about this trial

PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya

We'll reach out to this number within 24 hrs